Sudeep Pharma shares have surged nearly 75% from their initial public offering (IPO) price of ₹593 in less than a year, reflecting strong investor interest in the pharmaceutical company and its growth prospects. The stock made a robust debut on 28 November, listing at ₹730 per share on the NSE, a premium of 23.10% over its issue price. On the BSE, it debuted at ₹733.95, marking a 23.77% premium. According to reports from LiveMint, this performance demonstrates significant market confidence in the company's battery materials business positioning. As of October 14, 2026, Sudeep Pharma is trading at ₹1,053.80, representing a 3.90% gain from the previous closing price of ₹1,014.20, with a market capitalization of ₹11,947.42 crore. The stock has delivered 67.93% returns this year and trading in the range of ₹1,060.10 to ₹998.60.
Despite the strong performance, ICICI Securities believes the stock's valuation has run ahead of its fundamentals, maintaining its Hold rating while raising its target price to ₹1,000 from ₹700. As reported by LiveMint, the revised target remains below the closing market price of ₹1,018 on 13 October. The brokerage expects EBITDA from the company's core business to rise to ₹3.3 billion by FY29, implying a compound annual growth rate (CAGR) of 15% over FY26–FY29. At the current market price, Sudeep Pharma's total consolidated enterprise value stands at ₹119 billion, with the market assigning a residual enterprise value of ₹36 billion to its iron phosphate business. The company's TTM P/E ratio stands at 52.25, significantly higher than the sector average of 19.67, reflecting the premium valuation for its battery materials business.
According to LiveMint reports, Sudeep Pharma is uniquely positioned in India's battery materials market as the country's sole producer of iron phosphate. Its proprietary green technology gives it an advantage over domestic peers, while its product has already received approval from eight customers ahead of the commercialisation of its first-phase facility. The company's 25,000-tonne-per-annum (TPA) facility is expected to become operational in early FY28. Sudeep Pharma plans to expand capacity to 100,000–200,000 TPA by FY31 to cater to an estimated 100–200 gigawatt-hours (GWh) of lithium iron phosphate (LFP) battery capacity. The company reported a net profit of ₹172.89 crore in 2026, demonstrating its financial strength in its core pharmaceutical business.
As reported by LiveMint, ICICI Securities highlighted Sudeep Pharma's proprietary, ammonia-free production technology as a key differentiator in a market dominated by Chinese manufacturers. China has a strong cost advantage in iron phosphate production, supported by an established battery materials ecosystem and the use of ferrous sulphate, a low-cost byproduct of titanium dioxide manufacturing through the ammonia process. However, this route generates substantial wastewater and creates challenges related to byproduct disposal. Sudeep Advance Materials, a wholly owned subsidiary of Sudeep Pharma, uses a different iron source and a proprietary production process that does not rely on ammonia, significantly reducing effluent generation and offering a greener, potentially more scalable alternative to conventional manufacturing methods.
According to LiveMint reports, ICICI Securities cautioned that Sudeep Pharma's valuation already reflects significant expectations for its nascent battery chemicals business. Based on estimated iron phosphate segment EBITDA of ₹0.9 billion in FY29 and ₹2.3 billion in FY30, the market is valuing the battery chemicals business at an aggressive 39 times FY29 EBITDA and 16 times FY30 EBITDA. These valuations, the brokerage noted, leave limited room for execution setbacks. Despite the growth opportunity and the company's promising position in the battery materials segment, ICICI Securities has retained its Hold recommendation with a target price of ₹1,000 per share, believing the current valuation already reflects substantial optimism around the battery chemicals business. The company's mutual fund holding stands at 7.43% as of September 30, 2026, with FII holding at 2.93%, indicating growing institutional interest in the pharmaceutical and battery materials company.
